New product

Imbruvica 140 mg (Ibrutinib) 90 capsules

$26,000

IMBRUVICA 140 mg

90 capsules

Active ingredient:
  • Ibrutinib – 140 mg

Indications

This medication is prescribed in the following cases:

  • Patients diagnosed with waldenström's macroglobulinemia (WM);
  • Patients diagnosed with chronic graft versus host disease (cGVHD), after showing no results from either one or more lines of systemic treatment;
  • Patients diagnosed with either chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL);
  • Patients diagnosed with either chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with a 17p deletion;
  • Patients diagnosed with mantle cell lymphoma (MCL) who have received at least one prior treatment;
  • Patients diagnosed with marginal zone lymphoma (MZL) who require oral or intravenous medication (systemic therapy) and have received previous treatment of a certain type.

Contraindications

Ibrutinib should not be uses in patients diagnosed with severe hepatic impairment or hepatic disease, that correspond to the Child-Pugh scale, class C.

Side effects

The most commonly reported adverse reactions (≥20%) in patients diagnosed with B-cell malignancies (such as MCL, CLL/SLL, WM and MZL) were rash, bruising, anemia, neutropenia, hemorrhage, pyrexia, musculoskeletal pain, nausea, fatigue, thrombocytopenia and diarrhea. The most common adverse reactions (≥20%) in patients with cGVHD were diarrhea, hemorrhage, anemia, thrombocytopenia, muscle spasms, pneumonia, stomatitis, nausea, fatigue and bruising.

Manufacturer:

Pharmacyclics LLC, Sunnyvale, USA


DELIVERY WORLDWIDE


Also known as: Ibrutinib, Ibrunib, Ibrutix, Ibruxen, Butinib, Lucibru, Ibrutinix

Accessories

30 other products in the same category: